Literature DB >> 31200003

Renin-angiotensin system activation and imbalance of matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 in cold-induced stroke.

Yu-Ying Su1, Huan-Min Li2, Zhen-Xing Yan1, Ming-Chun Li1, Ji-Peng Wei1, Wen-Xia Zheng1, Si-Qin Liu1, Yi-Ting Deng1, Hui-Fang Xie3, Chun-Guang Li4.   

Abstract

AIMS: In the present study, we investigated the roles of renin-angiotensin system (RAS) activation and imbalance of matrix metalloproteinase-9 (MMP-9)/tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in cold-induced stroke during chronic hypertension, as well as the protective effects of captopril and recombinant human TIMP-1 (rhTIMP-1). MAIN
METHODS: Rats were randomly assigned to sham; 2-kidney, 2-clip (2K-2C); 2K-2C + captopril, and 2K-2C + rhTIMP-1 groups. After blood pressure values had stabilized, each group was randomly divided into an acute cold exposure (ACE) group (12-h light at 22 °C/12-h dark at 4 °C) and a non-acute cold exposure (NACE) group (12-h light/12-h dark at 22 °C), each of which underwent three cycles of exposure. Captopril treatment was administered via gavage (50 mg/kg/d), while rhTIMP-1 treatment was administered via the tail vein (60 μg/kg/36 h). KEY
FINDINGS: In the 2K-2C group, angiotensin II (AngII) and MMP-9 levels increased in both the plasma and cortex, while no such changes in TIMP-1 expression were observed. Cold exposure further upregulated AngII and MMP-9 levels and increased stroke incidence. Captopril and rhTIMP-1 treatment inhibited MMP-9 expression and activation and decreased stroke incidence in response to cold exposure. SIGNIFICANCE: The present study is the first to demonstrate that cold exposure exacerbates imbalance between MMP-9 and TIMP-1 by activating the RAS, which may be critical in the initiation of stroke during chronic hypertension. In addition, our results suggest that captopril and rhTIMP-1 exert protective effects against cold-induced stroke by ameliorating MMP-9/TIMP-1 imbalance.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  2-Clip; 2-Kidney; Angiotensin II; Captopril; Cold exposure; rhTIMP-1

Mesh:

Substances:

Year:  2019        PMID: 31200003     DOI: 10.1016/j.lfs.2019.116563

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Co‑expression of tissue kallikrein 1 and tissue inhibitor of matrix metalloproteinase 1 improves myocardial ischemia‑reperfusion injury by promoting angiogenesis and inhibiting oxidative stress.

Authors:  Shujie Huang; Meixian Chen; Huizhen Yu; Kaiyang Lin; Yansong Guo; Pengli Zhu
Journal:  Mol Med Rep       Date:  2020-12-23       Impact factor: 2.952

2.  Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo.

Authors:  Rolf Schreckenberg; Annemarie Wolf; Tamara Szabados; Kamilla Gömöri; István Adorján Szabó; Gergely Ágoston; Gábor Brenner; Péter Bencsik; Péter Ferdinandy; Rainer Schulz; Klaus-Dieter Schlüter
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

3.  Angiotensin-converting enzyme inhibitors increase anti-fibrotic biomarkers in African Americans with left ventricular hypertrophy.

Authors:  Cesar A Romero; Shobi Mathew; Benjamin Wasinski; Brian Reed; Aaron Brody; Rachelle Dawood; Michael J Twiner; Candace D McNaughton; Rafael Fridman; John M Flack; Oscar A Carretero; Phillip D Levy
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-03-10       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.